Aparato digestivo
Especialidad
Federico
Argüelles Arias
Publicaciones en las que colabora con Federico Argüelles Arias (22)
2024
-
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
-
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study
Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study
Alimentary pharmacology & therapeutics, Vol. 53, Núm. 12, pp. 1277-1288
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
-
Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study
BMJ Open Gastroenterology, Vol. 7, Núm. 1
2019
-
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428
-
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788
-
Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study
Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002
2018
-
Influence of age, body mass index and comorbidity on major outcomes in acute pancreatitis, a prospective nation-wide multicentre study
United European Gastroenterology Journal, Vol. 6, Núm. 10, pp. 1508-1518
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131